Bristol-Myers Squibb Company (BMY)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Bristol-Myers Squibb Company, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Bristol-Myers Squibb Company (BMY) has returned 13.77% so far this year and 4.47% over the past 12 months. Over the last ten years, BMY has returned 2.72% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jun 1, 1972, BMY's average daily return is +0.05%, while the average monthly return is +0.98%. At this rate, your investment would double in approximately 5.9 years.

Historically, 56% of months were positive and 44% were negative. The best month was Oct 1974 with a return of +42.1%, while the worst month was Apr 2002 at -28.4%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 8 months.

On a daily basis, BMY closed higher 48% of trading days. The best single day was Oct 21, 1987 with a return of +15.9%, while the worst single day was Apr 19, 2000 at -22.5%.

Bristol-Myers Squibb Company has an annualized alpha of 5.36%, beta of 0.79, and R² of 0.27 versus S&P 500 Index. Calculated based on daily prices since June 02, 1972.

• This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (87.12%) than losses (80.03%) — typical of diversified or defensive assets.
• R² of 0.27 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

BMY ranks 43 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Bristol-Myers Squibb Company (BMY) and compare them to a chosen benchmark (S&P 500 Index).

Bristol-Myers Squibb Company provided a 4.11% dividend yield over the last twelve months, with an annual payout of $2.49 per share. The company has been increasing its dividends for 4 consecutive years.

The table displays the monthly dividend distributions for Bristol-Myers Squibb Company. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Bristol-Myers Squibb Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bristol-Myers Squibb Company was 72.03%, occurring on Jul 24, 2002. Recovery took 2726 trading sessions.

The current Bristol-Myers Squibb Company drawdown is 13.61%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Bristol-Myers Squibb Company over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Bristol-Myers Squibb Company is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.